STRO: רווח נקי למניה (EPS TTM) Sutro Bio
Sutro Biopharma, Inc. (STRO) is gradually depleting its existing capital to fund costly clinical trials. This rolling 12-month EPS chart illustrates the current trend, with the metric currently at -17.58. Strategic alliances with pharma behemoths provide cash inflows, stabilizing free cash flow. However, uncertainty regarding trial outcomes and the high capital intensity of development create certain financial risks.
פילוחי נתונים אנליטיים מרוכזים עבור Sutro Biopharma Inc. (STRO)
The calculation model for this indicator is highly sensitive to operational efficiency and actual business profitability. This metric determines the portion of net income attributable to a single common share over a rolling year. For Sutro Biopharma, Inc. (STRO), which develops high-precision oncotherapeutic conjugates, this serves as an indicator of the monetization of its scientific research. Analyzing the per-share profit trend over the last 12 months allows for the separation of speculative noise from fundamental performance.
